Post Graduate Training:
Interventional Cardiology Fellowship
Section of Interventional Cardiology
University of Colorado Health Sciences Center
Denver, CO
Cardiovascular Disease Fellowship
Division of Cardiology
University of Colorado Health Sciences Center
Denver, CO
Chief Residency
Department of Medicine
University of Minnesota Hospital & Clinic
Minneapolis, MN
Residency
Internal Medicine Residency
University of Minnesota Hospital & Clinic
Minneapolis, MN
Education:
M.D.
Thomas Jefferson University, Jefferson Medical School
Philadelphia, PA
B.S.
University of Puget Sound
Major Emphasis: Biology
Tacoma, WA
August 1987 – May 1991
Board Certification:
American Board of Internal Medicine, Diplomat in Interventional Cardiology – 2003
American Board of Internal Medicine, Diplomat in Cardiovascular Disease – 2002
American Board of Internal Medicine, Diplomat in Internal Medicine – 1999
American College of Graduate Medical Education, Review Board Member – 1997
Research:
Clinical Research Trials as Primary Investigator:
SPIRIT IV: A Clinical Evaluation of the XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects with de novo Native Coronary Artery Lesions
CURRNT-Oasis 7: Randomized, multinational, double-blind study, comparing a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or myocardial infarction managed with an early invasive strategy
EVEREST II Cardiovascular Valve Repair System: Endovascular Valve Edge-to-Edge REpair STudy II (On-going)
Xience V: XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (currently in start-up phase)
Clinical Research Trials as Sub-Investigator:
Spirit III: to determine the safety and efficacy of the XIENCE™ V Everolimus Eluting Coronary Stent System (XIENCE™ V EECSS) for the treatment of subjects with a maximum of two de novo native coronary artery lesions
Athena: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atria Fibrillation/Atrial Flutter (AF/AFL) (ATHENA)) (closed July 2008)
RED-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia (closed 2008)
Dionysos: Randomized double blind trial to evaluate the efficacy and safety of dronedarone (400mg BID) versus amiodarone (600mg daily for 28 days, then 200mg daily thereafter) for at least 6 months for the maintenance of sinus rhythm in patients with atrial fibrillation (AF)
CRESCENDO: Randomized, multinational, multicenter, double-blind, placebo-controlled, two-arm parallel group trial of rimonabant 20-mg OD for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors
Cogentus CG104: A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease
Virgo: Variation in Recovery: Role of Gender on Outcomes in Acute Myocardial Infarction (AMI) Patients (VIRGO) (currently in start-up phase)
Current Directorships:
Director, Acute Myocardial Infarction (STEMI) Program, St. Patrick Hospital and Health Sciences Center/International Heart Institute of Montana
Medical Director, Clinical Research, St. Patrick Hosptial and Health Sciences Center/International Heart Institute of Montana
Director, Cardiac Catherization Laboratory, St. Patrick Hospital and Health Sciences Center/International Heart Institute of Montana